Skip to main navigation
Logo

Investors

Investors

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

Press Releases

Date Title and Summary
Toggle Summary May 15, 2013 Ultragenyx Advances Clinical Development of UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
Ultragenyx Advances Clinical Development of UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
Toggle Summary Jul 3, 2013 Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy
Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy
Toggle Summary Sep 3, 2013 Ultragenyx Announces Collaboration with Kyowa Hakko Kirin to Develop and Commercialize Phase 2-stage KRN23 for X-linked Hypophosphatemia
Ultragenyx Announces Collaboration with Kyowa Hakko Kirin to Develop and Commercialize Phase 2-stage KRN23 for X-linked Hypophosphatemia
View all press releases »
Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Investor FAQ
    • Contact Us

    Shareholder Tools

    • Email Alerts
    • Print
    • Share

  • Facebook
  • Google
  • LinkedIn
  • Twitter
  • RSS
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Message from BIO
  • Medicines
    • Crysvita®
    • Mepsevii™
  • Pipeline
    • Burosumab for XLH
    • Burosumab for TIO
    • Vestronidase alfa
    • UX007 for FAOD
    • UX007 for Glut1 DS
    • DTX 301 for OTC
    • DTX 401 for GSD1a
    • Presentations & Publications
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • Glut1 DS
    • OTC
    • GSD1a
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Investor FAQ
      • Contact Us
  • Careers
    • Commitment
    • Benefits
    • Interns
    • Jobs
  • Partnering
    • Current Partnerships
  • Contact
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Message from BIO
    • Medicines
      • Crysvita®
      • Mepsevii™
  • Pipeline
    • Burosumab for XLH
    • Burosumab for TIO
    • Vestronidase alfa
    • UX007 for FAOD
    • UX007 for Glut1 DS
    • DTX 301 for OTC
    • DTX 401 for GSD1a
    • Presentations & Publications
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • Glut1 DS
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Investor FAQ
      • Contact Us
  • Careers
    • Commitment
    • Benefits
    • Interns
    • Jobs
    Partnering
    • Current Partnerships
    Contact
    • Driving Directions
  • Privacy Policy
© 2018 Ultragenyx Pharmaceutical Inc.Website Design: Hane Chow, Inc.
  • Privacy Policy